Melanoma highlights from ESMO 2019

Melanoma highlights from ESMO 2019

Publication date: Oct 17, 2019

Dr Teresa Amaral speaks to ecancer at ESMO 2019 in Barcelona about melanoma studies that stood out at the conference.

Dr Amaral begins by talking about research in the neoadjuvant setting, including the 2-year follow-up results of a large phase II trial looking at TVEC in neoadjuvant treatment versus surgery alone in patients with resectable stage IIIBO-IVM1a melanoma and two Dutch trials that were presented investigating the combination of ipilimumab and nivolumab. She also comments on the biomarker study analysis being presented at the conference with regards to immunotherapy.

In the metastatic and adjuvant setting, she comments on the 3-year efficacy and biomarker results from the CheckMate 238 trial, discusses what the IMMUNED study results meant for the recommended duration of combined immunotherapy and talks about what can be understood from the 5-year update results from the CheckMate 067 trial.

Dr Amaral also explains why the data presented on the ABC trial – which is an update on the combination of nivolumab and ipilimumab versus nivolumab alone in patients with asymptomatic melanoma brain metastases – indicates that it is important to provide this combination in the first-line setting.

To conclude, Dr Amaral summarises many of the reoccurring aspects of the above studies, and suggests what clinicians can take away from the highlights of this meeting.

Concepts Keywords
Adjuvant Evidence disease
Amaral Surgery disease
Angel Melanoma
Asymptomatic Higher tools
Barcelona Presentation travel
Beer Neoadjuvant treatment
Biomarker Surgery surgery
Biomarkers Hormonal therapy
Checkmate Immunotherapy
Comparator Medicine
Congress Clinical medicine
Dhe Health
Dutch RTT
England Bristol-Myers Squibb
Hormonal Therapy Cancer treatments
Immune System Antineoplastic drugs
Immunotherapy Breakthrough therapy
Inhibitor Melanoma
Interferon Gamma Ipilimumab
Ipilimumab Immunotherapy
James Larkin
Legion
Melanoma
Metastatic
Mina
Mono
Monotherapy
Mutation
Navel
Neoadjuvant
Placebo
Regiment
Relapse
Sheamus
Spectrum
Stirrup
Tea
Thes
TMB
Toxicity
Trabant

Semantics

Type Source Name
disease MESH Melanoma
disease DOID Melanoma
pathway BSID Melanoma
gene UNIPROT LARGE1
drug DRUGBANK Ipilimumab
drug DRUGBANK Nivolumab
drug DRUGBANK Abacavir
disease MESH metastases

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *